US › Healthcare

Evotec SE ADR (EVO)

US · Healthcare · Drug Manufacturers - Specialty & Generic

$1.67+2.45%

Last close · 2026-09-17

Latest quarter · ended 2026-06-30

Revenue

$145.9M

Revenue YoY

-14.8%

Net profit

$-47.4M

EPS

$-0.13

EPS estimate

$-0.04

Net margin

-32.5%

EPS came in at -0.13 against a street estimate of -0.04 — a miss of 225.0%.

Key statistics

Market cap

$579.3M

Forward P/E

20.6

P/B

0.77

Book value

$2.17

EPS (TTM)

$-0.63

52-week high

$4.27

52-week low

$1.60

50-day MA

$2.04

200-day MA

$2.80

Beta

1.26

Analyst view

Analysts rate Evotec SE ADR a buy (4 buy, 1 hold, 1 sell out of 6) with an average price target of $4.32.

Shareholding

Insiders

0.01%

Institutions

0.81%

Largest institutional holders

Fund	Stake
Mubadala Investment Company PJSC	1.29%
DCF Advisers, LLC	0.30%
WCM Investment Management	0.18%
ABC arbitrage SA	0.10%
Optiver Holding B.V.	0.08%
Morgan Stanley - Brokerage Accounts	0.07%
LPL Financial Corp	0.03%
Citadel Advisors Llc	0.02%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Evotec SE ADR — free to start.

Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc Merck & Company Inc UnitedHealth Group Incorporated Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Amgen Inc Novo Nordisk A/S Gilead Sciences Inc Abbott Laboratories

Data updated 2026-09-18.